| Year |
Citation |
Score |
| 2024 |
Leveille E, Kothari S, Cosgun KN, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery. 14: 1577-1580. PMID 39228298 DOI: 10.1158/2159-8290.CD-24-0644 |
0.305 |
|
| 2023 |
Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira AV, Pfeuffer L, Fens MHAM, Lu J, Kuster B, Engleitner T, Heidegger S, Rad R, Ringshausen I, Zenz T, Wendtner CM, et al. Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Reports. 42: 113017. PMID 37792532 DOI: 10.1016/j.celrep.2023.113017 |
0.407 |
|
| 2023 |
Ogana HA, Hurwitz S, Hsieh CL, Geng H, Müschen M, Bhojwani D, Wolf MA, Larocque J, Lieber MR, Kim YM. Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia. Frontiers in Cell and Developmental Biology. 11: 1134121. PMID 37082620 DOI: 10.3389/fcell.2023.1134121 |
0.478 |
|
| 2023 |
Cosgun KN, Jumaa H, Robinson ME, Kistner KM, Xu L, Xiao G, Chan LN, Lee J, Kume K, Leveille E, Fonseca-Arce D, Khanduja D, Ng HL, Feldhahn N, Song J, et al. Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignancies. Biorxiv : the Preprint Server For Biology. PMID 36993619 DOI: 10.1101/2023.03.13.532152 |
0.304 |
|
| 2023 |
Lee J, Robinson ME, Sun R, Kume K, Ma N, Cosgun KN, Chan LN, Leveille E, Geng H, Vykunta VS, Shy BR, Marson A, Katz S, Chen J, Paietta E, et al. Dynamic phosphatase-recruitment controls B-cell selection and oncogenic signaling. Biorxiv : the Preprint Server For Biology. PMID 36993276 DOI: 10.1101/2023.03.13.532151 |
0.49 |
|
| 2023 |
Chen Z, Zhou K, Xue J, Small A, Xiao G, Nguyen LXT, Zhang Z, Prince E, Weng H, Huang H, Zhao Z, Qing Y, Shen C, Li W, Han L, et al. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. Science Translational Medicine. 15: eabq8513. PMID 36989375 DOI: 10.1126/scitranslmed.abq8513 |
0.512 |
|
| 2023 |
Taghi Khani A, Kumar A, Sanchez Ortiz A, Radecki KC, Aramburo S, Lee SJ, Hu Z, Damirchi B, Lorenson MY, Wu X, Gu Z, Stohl W, Sanz I, Meffre E, Müschen M, et al. Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms. Communications Biology. 6: 295. PMID 36941341 DOI: 10.1038/s42003-023-04667-8 |
0.741 |
|
| 2022 |
Leveille E, Kothari S, Müschen M. Genetic Modeling of B-cell State Transitions for Rational Design of Lymphoma Therapies. Blood Cancer Discovery. OF1-OF4. PMID 36534735 DOI: 10.1158/2643-3230.BCD-22-0180 |
0.308 |
|
| 2022 |
Leveille E, Chan LN, Mirza AS, Kume K, Müschen M. SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. Cellular Signalling. 94: 110331. PMID 35398488 DOI: 10.1016/j.cellsig.2022.110331 |
0.578 |
|
| 2022 |
Geron I, Savino AM, Fishman H, Tal N, Brown J, Turati VA, James C, Sarno J, Hameiri-Grossman M, Lee YN, Rein A, Maniriho H, Birger Y, Zemlyansky A, Muler I, et al. An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia. Nature Communications. 13: 659. PMID 35115489 DOI: 10.1038/s41467-022-28218-7 |
0.504 |
|
| 2022 |
Ketzer F, Abdelrasoul H, Vogel M, Marienfeld R, Müschen M, Jumaa H, Wirth T, Ushmorov A. CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia. Oncogenesis. 11: 1. PMID 35013097 DOI: 10.1038/s41389-021-00377-0 |
0.5 |
|
| 2021 |
Contreras-Trujillo H, Eerdeng J, Akre S, Jiang D, Contreras J, Gala B, Vergel-Rodriguez MC, Lee Y, Jorapur A, Andreasian A, Harton L, Bramlett CS, Nogalska A, Xiao G, Lee JW, et al. Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. Nature Communications. 12: 6522. PMID 34764253 DOI: 10.1038/s41467-021-26771-1 |
0.345 |
|
| 2021 |
Chan TY, Egbert CM, Maxson JE, Siddiqui A, Larsen LJ, Kohler K, Balasooriya ER, Pennington KL, Tsang TM, Frey M, Soderblom EJ, Geng H, Müschen M, Forostyan TV, Free S, et al. TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications. 12: 5337. PMID 34504101 DOI: 10.1038/s41467-021-25622-3 |
0.32 |
|
| 2021 |
Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Atri P, Müschen M, Tissot FLH, Miser J, et al. Protein phosphatase 2A as a therapeutic target in small cell lung cancer. Molecular Cancer Therapeutics. PMID 34253596 DOI: 10.1158/1535-7163.MCT-21-0013 |
0.308 |
|
| 2021 |
Chan LN, Aghania E, Leveille E, Müschen M. Metabolic determinants of B-cell selection. Biochemical Society Transactions. 49: 1467-1478. PMID 34196360 DOI: 10.1042/BST20201316 |
0.503 |
|
| 2021 |
Ecker V, Stumpf M, Brandmeier L, Neumayer T, Pfeuffer L, Engleitner T, Ringshausen I, Nelson N, Jücker M, Wanninger S, Zenz T, Wendtner C, Manske K, Steiger K, Rad R, et al. Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. Nature Communications. 12: 3526. PMID 34112805 DOI: 10.1038/s41467-021-23752-2 |
0.425 |
|
| 2021 |
Sadras T, Martin M, Kume K, Robinson ME, Saravanakumar S, Lenz G, Chen Z, Song JY, Siddiqi T, Oksa L, Knapp AM, Cutler J, Cosgun KN, Klemm L, Ecker V, et al. Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular Cell. PMID 33878293 DOI: 10.1016/j.molcel.2021.03.043 |
0.547 |
|
| 2021 |
Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, et al. Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature. PMID 33712811 DOI: 10.1038/s41586-021-03388-4 |
0.425 |
|
| 2021 |
Pan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN, Xu L, Kume K, Sadras T, Wang S, et al. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33531346 DOI: 10.1073/pnas.2016553118 |
0.483 |
|
| 2020 |
Sadras T, Müschen M. Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL. Blood Cancer Discovery. 1: 18-20. PMID 34661138 DOI: 10.1158/2643-3249.BCD-20-0078 |
0.43 |
|
| 2020 |
Sadras T, Chan LN, Xiao G, Müschen M. Metabolic Gatekeepers of Pathological B Cell Activation. Annual Review of Pathology. PMID 33321055 DOI: 10.1146/annurev-pathol-061020-050135 |
0.513 |
|
| 2020 |
Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, et al. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature. PMID 33149299 DOI: 10.1038/s41586-020-2884-6 |
0.558 |
|
| 2020 |
Chen Y, Xu L, Lin RY, Müschen M, Koeffler HP. Core transcriptional regulatory circuitries in cancer. Oncogene. PMID 32943730 DOI: 10.1038/S41388-020-01459-W |
0.372 |
|
| 2020 |
Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, et al. Signalling input from divergent pathways subverts B cell transformation. Nature. PMID 32699415 DOI: 10.1038/S41586-020-2513-4 |
0.729 |
|
| 2020 |
Abdelrasoul H, Vadakumchery A, Werner M, Lenk L, Khadour A, Young M, El Ayoubi O, Vogiatzi F, Krämer M, Schmid V, Chen Z, Yousafzai Y, Cario G, Schrappe M, Müschen M, et al. Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Nature Communications. 11: 3194. PMID 32581241 DOI: 10.1038/S41467-020-16927-W |
0.456 |
|
| 2020 |
Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. PMID 32531268 DOI: 10.1016/J.Ccell.2020.04.017 |
0.381 |
|
| 2020 |
Song C, Ge Z, Ding Y, Tan BH, Desai D, Gowda K, Amin SG, Gowda R, Robertson G, Yue F, Huang S, Spiegelman V, Payne J, Reeves M, Gurel Z, et al. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia. Blood. PMID 32396934 DOI: 10.1182/Blood.2019002655 |
0.545 |
|
| 2020 |
Gang EJ, Kim HN, Hsieh YT, Ruan Y, Ogana H, Pham J, Lee S, Geng H, Park E, Klemm L, Willman CL, Carroll WL, Mittelman SD, Orgel E, Oberley MJ, et al. Integrin α6 mediates drug resistance of acute lymphoblastic B-cell leukemia. Blood. PMID 32219444 DOI: 10.1182/Blood.2019001417 |
0.447 |
|
| 2020 |
Sadras T, Müschen M. MEF2D Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL Blood Cancer Discovery. 1: 18-20. DOI: 10.1158/2643-3249.bcd-20-0078 |
0.384 |
|
| 2019 |
Rodríguez-Hernández G, Opitz FV, Delgado P, Walter C, Álvarez-Prado ÁF, González-Herrero I, Auer F, Fischer U, Janssen S, Bartenhagen C, Raboso-Gallego J, Casado-García A, Orfao A, Blanco O, Alonso-López D, et al. Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. Nature Communications. 10: 5563. PMID 31804490 DOI: 10.1038/S41467-019-13570-Y |
0.565 |
|
| 2019 |
Xiu Y, Dong Q, Fu L, Bossler A, Tang X, Boyce B, Borcherding N, Leidinger M, Sardina JL, Xue HH, Li Q, Feldman A, Aifantis I, Boccalatte F, Wang L, et al. Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion. Blood. PMID 31697816 DOI: 10.1182/Blood.2019001438 |
0.623 |
|
| 2019 |
Müschen M. Origins of the human B-cell lineage. Blood. 134: 998-999. PMID 31558555 DOI: 10.1182/Blood.2019002573 |
0.524 |
|
| 2019 |
Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Science Translational Medicine. 11. PMID 31554741 DOI: 10.1126/Scitranslmed.Aaw9414 |
0.429 |
|
| 2019 |
Tan YT, Ye L, Xie F, Wang J, Müschen M, Chen SJ, Kan YW, Liu H. The CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1 mouse model. Haematologica. PMID 31537693 DOI: 10.3324/Haematol.2019.229013 |
0.364 |
|
| 2019 |
Hurtz C, Chan LN, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Chen CW, Armstrong SA, Chen J, Ernst P, Melnick A, Milne T, Müschen M. Rationale for targeting BCL6 in -rearranged acute lymphoblastic leukemia. Genes & Development. PMID 31395741 DOI: 10.1101/Gad.327593.119 |
0.599 |
|
| 2019 |
Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, Wang Z, Shen Y, Li M, Wang H, Sun J, Nguyen LX, Zhang H, Jiang W, Yang Y, et al. Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia. Blood. PMID 31395602 DOI: 10.1182/Blood.2019002457 |
0.389 |
|
| 2019 |
Ngo VN, Müschen M. Chemical choreography of germinal center B-cell migration. Cell Research. PMID 31024167 DOI: 10.1038/S41422-019-0170-7 |
0.527 |
|
| 2019 |
Müschen M. Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation. Nature Reviews. Immunology. PMID 30890785 DOI: 10.1038/S41577-019-0154-3 |
0.52 |
|
| 2019 |
Chan LN, Hurtz C, Geng H, Ballabio E, Xiao G, Deb G, Khoury H, Armstrong SA, Ernst P, Melnick A, Milne TA, Müschen M. Rationale for Targeting BCL6 in MLL-Rearranged B-ALL Blood. 134: 1239-1239. DOI: 10.1182/Blood-2019-131565 |
0.592 |
|
| 2019 |
Lee J, Kume K, Chen Z, Xiao G, Cosgun KNN, Chen L, Chan LN, Klemm L, Chen CD, Ma N, Chan WC, Forman SJ, Zammarchi F, Van Berkel P, Melnick A, et al. Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling Blood. 134: 393-393. DOI: 10.1182/Blood-2019-131270 |
0.504 |
|
| 2019 |
Chan LN, Murakami MA, Caesar R, Hurtz C, Kume K, Sadras T, Shojaee S, Pölönen P, Ugale A, Lee J, Cosgun KN, Geng H, Heinäniemi M, Lohi O, Wiita AP, et al. Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation Blood. 134: 3944-3944. DOI: 10.1182/Blood-2019-130774 |
0.729 |
|
| 2019 |
Kume K, Chen L, Lee J, Müschen M. Autonomous Ca2+ Oscillations Reflect Oncogenic Signaling in B-ALL Cells Blood. 134: 1253-1253. DOI: 10.1182/Blood-2019-130708 |
0.45 |
|
| 2019 |
Qin X, Su R, Yang L, Chan AKN, Deng X, Qing Y, Klemm L, Müschen M, Chen CD, Chen J. Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening Blood. 134: 1465-1465. DOI: 10.1182/Blood-2019-129849 |
0.471 |
|
| 2019 |
Sadras T, Martin M, Kim-Sing L, Cutler J, Lenz G, Knapp AM, Ghergus D, Delmotte F, Schleiss C, Korganow A, Soulas-Sprauel P, Chen Z, Pandey A, Weinstock DM, Jumaa H, et al. Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies Blood. 134: 295-295. DOI: 10.1182/Blood-2019-128999 |
0.675 |
|
| 2019 |
Xiao G, Kume K, Geng H, Han TT, Klemm L, Müschen M. Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL Blood. 134: 3785-3785. DOI: 10.1182/Blood-2019-128719 |
0.405 |
|
| 2019 |
Lee J, Xiao G, Cosgun KNN, Geng H, Ma N, Chan LN, Kume K, Nix M, Chen Z, Chen CD, Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, et al. Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis Blood. 134: 2782-2782. DOI: 10.1182/Blood-2019-127615 |
0.632 |
|
| 2019 |
Cosgun KN, Deb G, Yang X, Xiao G, Sadras T, Lee J, Chan LN, Kume K, Yang L, Geng H, Chan J, Song JY, Jumaa H, Polson AG, Clevers H, et al. Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation Blood. 134: 748-748. DOI: 10.1182/Blood-2019-127263 |
0.6 |
|
| 2019 |
Pan L, Hong C, Xiao G, Geng H, Wang S, Müschen M. Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions Blood. 134: 746-746. DOI: 10.1182/Blood-2019-125171 |
0.362 |
|
| 2019 |
Su R, Dong L, Li Y, Han L, Gao M, Wunderlich M, Deng X, Li H, Gao L, Li C, Robison S, Tan B, Qing Y, Qin X, Prince E, et al. Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance Blood. 134: 233-233. DOI: 10.1182/Blood-2019-124535 |
0.463 |
|
| 2019 |
Kwak LW, Qin H, Dong Z, Wang X, Cheng WA, Smith D, Song JY, Aldoss I, Muschen M, Forman SJ. Novel BAFF-R CAR T-cell Therapy for CD19 Antigen-loss Relapsed B Cell Tumors Hematological Oncology. 37: 165-166. DOI: 10.1002/Hon.123_2629 |
0.441 |
|
| 2018 |
Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. PMID 30530749 DOI: 10.1182/Blood-2018-05-851667 |
0.478 |
|
| 2018 |
Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, et al. Author Correction: Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. PMID 29849140 DOI: 10.1038/S41586-018-0164-5 |
0.592 |
|
| 2018 |
Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, Zhang QC, Aghajanirefah A, Cosgun KN, Sadras T, Lee J, Mirzapoiazova T, Salgia R, Ernst T, Hochhaus A, et al. B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. PMID 29551267 DOI: 10.1016/J.Cell.2018.02.048 |
0.57 |
|
| 2018 |
Martín-Lorenzo A, Auer F, Chan LN, García-Ramírez I, Gonzalez-Herrero I, Rodríguez-Hernández G, Bartenhagen C, Dugas M, Gombert M, Ginzel S, Blanco O, Orfao A, Alonso-López D, De Las Rivas J, Begoña García-Cenador M, et al. Loss of Pax5 exploits Sca1-BCR-ABLp190 susceptibility to confer the metabolic shift essential for pB-ALL. Cancer Research. PMID 29490943 DOI: 10.1158/0008-5472.CAN-17-3262 |
0.435 |
|
| 2018 |
Pollock SB, Hu A, Mou Y, Martinko AJ, Julien O, Hornsby M, Ploder L, Adams JJ, Geng H, Müschen M, Sidhu SS, Moffat J, Wells JA. Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. Proceedings of the National Academy of Sciences of the United States of America. PMID 29476010 DOI: 10.1073/Pnas.1721899115 |
0.444 |
|
| 2018 |
Müschen M. Autoimmunity checkpoints as therapeutic targets in B cell malignancies. Nature Reviews. Cancer. PMID 29302068 DOI: 10.1038/nrc.2017.111 |
0.566 |
|
| 2018 |
Lee J, Kume K, Chen Z, Xiao G, Cosgun KN, Chan LN, Chen C, Pillai R, Chan WC, Forman SJ, Kwak LW, Zammarchi F, Van Berkel P, Weinstock DM, Melnick AM, ... ... Muschen M, et al. CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies Blood. 132: 776-776. DOI: 10.1182/Blood-2018-99-117553 |
0.529 |
|
| 2018 |
Qin H, Dong Z, Wang X, Cheng W, Smith DL, Song JY, Aldoss I, Muschen M, Forman SJ, Kwak LW. Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors Blood. 132: 1411-1411. DOI: 10.1182/Blood-2018-99-117513 |
0.418 |
|
| 2018 |
Lee J, Geng H, Dinson DS, Xiao G, Cosgun KN, Chan LN, Chen Z, Farzan M, Jung JU, Wiita AP, Muschen M. IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation Blood. 132: 552-552. DOI: 10.1182/Blood-2018-99-117472 |
0.574 |
|
| 2018 |
Kume K, Chen L, Lee J, Muschen M. Autonomous Ca2+ Oscillations Reflect Oncogenic BCR-Signaling in Multiple B-Cell Malignancies and Are Essential for Survival and Proliferation Blood. 132: 1373-1373. DOI: 10.1182/Blood-2018-99-117315 |
0.483 |
|
| 2018 |
Ecker V, Braun M, Neumayer T, Muschen M, Ruland J, Buchner M. SHIP1 Inhibition As Novel Therapeutic Approach in Chronic Lymphocytic Leukemia Blood. 132: 894-894. DOI: 10.1182/Blood-2018-99-117053 |
0.317 |
|
| 2018 |
Braun M, Ecker V, Neumayer T, Muschen M, Ruland J, Buchner M. DUSP1/6 Inhibition Reduces Tumor Cells and Activates Immune Response in Chronic Lymphocytic Leukemia Blood. 132: 2857-2857. DOI: 10.1182/Blood-2018-99-117052 |
0.37 |
|
| 2018 |
Cosgun KN, Deb G, Yang X, Xiao G, Sadras T, Auer F, Lee J, Abarientos A, Mangolini M, Aghajanirefah A, Geng H, Jumaa H, Polson AG, Clevers H, Muschen M. Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies Blood. 132: 547-547. DOI: 10.1182/Blood-2018-99-116956 |
0.541 |
|
| 2018 |
Sadras T, Cutler J, Aguade-Gorgorio J, Chen Z, Cosgun KN, Pandey A, Muschen M. Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies Blood. 132: 3922-3922. DOI: 10.1182/Blood-2018-99-116954 |
0.64 |
|
| 2018 |
Chan LN, Shojaee S, Hurtz C, Auer F, Chen Z, Cosgun KN, Geng H, Sadras T, White DL, Muschen M. Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia Blood. 132: 568-568. DOI: 10.1182/Blood-2018-99-115536 |
0.56 |
|
| 2018 |
Cosgun KN, Hendriks RW, Dickins RA, Heisterkamp N, Muschen M. Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia Blood. 132: 570-570. DOI: 10.1182/Blood-2018-99-115522 |
0.316 |
|
| 2018 |
Chan LN, Hurtz C, Geng H, Auer F, Chen Z, Xiao G, Lee J, Cosgun KN, Ye BH, Muschen M. Ras-Driven B-Cell Transformation Targets Developmental Rewiring of Cytokine to Pre-B Cell Receptor Signaling Blood. 132: 1336-1336. DOI: 10.1182/Blood-2018-99-115514 |
0.555 |
|
| 2018 |
Zhu Y, He X, Dong H, Sun J, Wang H, Zhang L, Miao Y, Jin J, Shen Y, Chen J, Muschen M, Chen C, Konopleva MY, Sun W, Zhang B, et al. Inhibition of PRMT1 Mediated FLT3 Arginine Methylation As a Potent Therapeutic Strategy for MLL-r ALL Blood. 132: 892-892. DOI: 10.1182/Blood-2018-99-115139 |
0.341 |
|
| 2018 |
Chen Z, Muschen M. Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies Blood. 132: 1587-1587. DOI: 10.1182/BLOOD-2018-99-113674 |
0.571 |
|
| 2018 |
Cosgun KN, Hecht A, Yang X, Mangolini M, Aghajanirefah A, Xiao G, Sadras T, Chen Z, Klemm L, Geng H, Hong C, Song Q, Zeng D, Jumaa H, Zeng D, ... ... Muschen M, et al. Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies Cancer Research. 78: 4515-4515. DOI: 10.1158/1538-7445.Am2018-4515 |
0.602 |
|
| 2018 |
Kume K, Chen L, Lee J, Müschen M. Abstract 4371: Store-operated Ca2+ entry and NFATC1-activation control oncogenic signaling in B-cell transformation and leukemogenesis Cancer Research. 78: 4371-4371. DOI: 10.1158/1538-7445.Am2018-4371 |
0.547 |
|
| 2018 |
Lee J, Geng H, Chen Z, Xiao G, Cosgun KN, Zammarchi F, Berkel PV, Melnick A, Paietta E, Muschen M. Abstract 2983: CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies Cancer Research. 78: 2983-2983. DOI: 10.1158/1538-7445.Am2018-2983 |
0.439 |
|
| 2018 |
Cosgun KN, Yang X, Mangolini M, Xiao G, Abarientos A, Aghajanirefah A, Klemm L, Sadras T, Geng H, Yang L, Song Q, Zeng D, Zeng D, Jumaa H, Polson A, ... ... Muschen M, et al. LGR5 Mediates Positive B-Cell Selection and is Critical for Survival of Normal and Transformed B Cells Experimental Hematology. 64: S59-S60. DOI: 10.1016/J.Exphem.2018.06.206 |
0.48 |
|
| 2018 |
Sadras T, Chen Z, Klemm L, Cosgun KN, Müschen M. T-Cell Associated ZAP70 Kinase Contributes to B-Cell Receptor Signaling in Malignant Lymphopoiesis Experimental Hematology. 64. DOI: 10.1016/J.Exphem.2018.06.137 |
0.557 |
|
| 2018 |
Müschen M. Autoimmunity Checkpoints in B-Cell Lineage ALL Clinical Lymphoma, Myeloma & Leukemia. 18. DOI: 10.1016/J.Clml.2018.06.054 |
0.578 |
|
| 2017 |
Wang L, Müschen M. Portending death in germinal centers - when B cells know their time is up. Cell Research. PMID 29192678 DOI: 10.1038/cr.2017.151 |
0.458 |
|
| 2017 |
Cao Q, Zhao X, Bai J, Gery S, Sun H, Lin DC, Chen Q, Chen Z, Mack L, Yang H, Deng R, Shi X, Chong LW, Cho H, Xie J, et al. Circadian clock cryptochrome proteins regulate autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29109286 DOI: 10.1073/Pnas.1619119114 |
0.58 |
|
| 2017 |
Deng R, Hurtz C, Song Q, Yue C, Xiao G, Yu H, Wu X, Muschen M, Forman S, Martin PJ, Zeng D. Extrafollicular CD4(+) T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nature Communications. 8: 978. PMID 29042531 DOI: 10.1038/S41467-017-00880-2 |
0.382 |
|
| 2017 |
Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, et al. Targeting the vulnerability to NAD(+) depletion in B-cell acute lymphoblastic leukemia. Leukemia. PMID 28904384 DOI: 10.1038/leu.2017.281 |
0.511 |
|
| 2017 |
Gugliotta G, Sudo M, Cao Q, Lin DC, Sun H, Takao S, Le Moigne R, Rolfe M, Gery S, Müschen M, Cavo M, Koeffler HP. Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. Neoplasia (New York, N.Y.). 19: 750-761. PMID 28843399 DOI: 10.1016/J.Neo.2017.08.001 |
0.557 |
|
| 2017 |
Chan LN, Müschen M. B cell identity as a metabolic barrier against malignant transformation. Experimental Hematology. PMID 28655536 DOI: 10.1016/j.exphem.2017.06.004 |
0.469 |
|
| 2017 |
Rodríguez-Hernández G, Hauer J, Martín-Lorenzo A, Schäfer D, Bartenhagen C, García-Ramírez I, Auer F, Gonzalez-Herrero I, Ruiz-Roca L, Gombert M, Okpanyi V, Fischer U, Chen C, Dugas M, Bhatia S, et al. Infection exposure promotes ETV6-RUNX1 precursor B cell leukemia via impaired H3K4 demethylases. Cancer Research. PMID 28630052 DOI: 10.1158/0008-5472.Can-17-0701 |
0.466 |
|
| 2017 |
Vo TT, Lee JS, Nguyen D, Lui B, Pandori W, Khaw A, Mallya S, Lu M, Müschen M, Konopleva M, Fruman DA. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Molecular Cancer Therapeutics. PMID 28566433 DOI: 10.1158/1535-7163.Mct-17-0024 |
0.585 |
|
| 2017 |
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, ... ... Muschen M, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. The Journal of Clinical Investigation. PMID 28481221 DOI: 10.1172/Jci90825 |
0.43 |
|
| 2017 |
Kruth K, Fang M, Shelton DN, Abu-Halawa O, Mahling R, Yang H, Weissman JS, Loh ML, Müschen M, Tasian SK, Bassik MC, Kampmann M, Pufall MA. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood. PMID 28424165 DOI: 10.1182/Blood-2017-02-766204 |
0.603 |
|
| 2017 |
Katerndahl CD, Heltemes-Harris LM, Willette MJ, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KA, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Müschen M, et al. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nature Immunology. PMID 28369050 DOI: 10.1038/Ni.3716 |
0.44 |
|
| 2017 |
Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Watkins A, Yang H, Ding LW, Jiang YY, Tyner JW, Ching J, et al. BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. PMID 28356518 DOI: 10.1073/Pnas.1609758114 |
0.495 |
|
| 2017 |
Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N. Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. Cell Reports. 18: 1687-1698. PMID 28199841 DOI: 10.1016/J.Celrep.2017.01.057 |
0.373 |
|
| 2017 |
Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 1-5. PMID 28192788 DOI: 10.1038/Nature21076 |
0.668 |
|
| 2017 |
Schjerven H, Ayongaba EF, Aghajanirefah A, McLaughlin J, Cheng D, Geng H, Boyd JR, Eggesbø LM, Lindeman I, Heath JL, Park E, Witte ON, Smale ST, Frietze S, Müschen M. Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1 pre-B ALL. The Journal of Experimental Medicine. 214: 793-814. PMID 28190001 DOI: 10.1084/Jem.20160049 |
0.419 |
|
| 2017 |
Xiao G, Hong C, Geng H, Muschen M. PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases Blood. 130: 882-882. DOI: 10.1182/BLOOD.V130.SUPPL_1.882.882 |
0.568 |
|
| 2017 |
Cosgun KNN, Hecht A, Yang X, Mangolini M, Aghajanirefah A, Chen Z, Xiao G, Klemm L, Hong C, Geng H, Jumaa H, Clevers H, Muschen M. Lgr5 Functions As Negative Regulator of Wnt Signaling in B Cells and Is Critical for Self-Renewal of Normal and Transformed B Cells Blood. 130: 3989-3989. DOI: 10.1182/Blood.V130.Suppl_1.3989.3989 |
0.667 |
|
| 2017 |
Lahnalampi M, Mehtonen J, Teppo S, Laukkanen S, Oksa L, Muschen M, Lohi O, Heinäniemi M. Genome-Wide Analysis of the Regulatory Landscape in Different Pre-B-ALL Subtypes Blood. 130: 3807-3807. DOI: 10.1182/Blood.V130.Suppl_1.3807.3807 |
0.476 |
|
| 2017 |
Kume K, Chen L, Lee J, Muschen M. Ca2+ Oscillations and NFATC1 -Activation Enable Oncogenic Signaling in Pre-B Cell Transformation and Leukemogenesis Blood. 130: 2500-2500. DOI: 10.1182/Blood.V130.Suppl_1.2500.2500 |
0.452 |
|
| 2017 |
Chan LN, Chen Z, Xiao G, Lee JW, Cosgun KN, Geng H, Cazzaniga V, Schjerven H, Dickins RA, Muschen M. Abstract 93: Transcriptional control of glucocorticoid responses in leukemia Cancer Research. 77: 93-93. DOI: 10.1158/1538-7445.Am2017-93 |
0.626 |
|
| 2017 |
Xu L, Chen Y, Dutra-Clarke M, Mayakonda A, Hazawa M, Savinoff SE, Doan N, Said JW, Yong WH, Yang H, Ding L, Jiang Y, Tyner JW, Ching J, Kovalik J, et al. Abstract 2569: BCL6 promotes glioma and serves as a novel therapeutic target Cancer Research. 77: 2569-2569. DOI: 10.1158/1538-7445.Am2017-2569 |
0.301 |
|
| 2017 |
Chen Y, Xu L, Dutra-Clarke M, Mayakonda A, Lin D, Koh L, Chong YK, Sandanaraj E, Madan V, Yang H, Doan N, Said JW, Yong WH, Müschen M, Ang BT, et al. Abstract 1524: BCL6 modulates the TP53 and STAT pathways in glioma Cancer Research. 77: 1524-1524. DOI: 10.1158/1538-7445.Am2017-1524 |
0.456 |
|
| 2016 |
Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE, Burger JA. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood. PMID 28031181 DOI: 10.1182/Blood-2016-06-722900 |
0.642 |
|
| 2016 |
McCracken AN, McMonigle RJ, Tessier J, Fransson R, Perryman MS, Chen B, Keebaugh A, Selwan E, Barr SA, Kim SM, Roy SG, Liu G, Fallegger D, Sernissi L, Brandt C, et al. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. Leukemia. PMID 27573555 DOI: 10.1038/Leu.2016.244 |
0.378 |
|
| 2016 |
Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, Peled A, Davis RE, Konopleva M, Burger JA. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. British Journal of Haematology. PMID 27071778 DOI: 10.1111/Bjh.14075 |
0.604 |
|
| 2016 |
Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Muschen M, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/J.Ccell.2016.03.008 |
0.306 |
|
| 2016 |
Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine. PMID 26974310 DOI: 10.1038/Nm.4062 |
0.771 |
|
| 2016 |
Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, et al. Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. PMID 26958840 DOI: 10.1038/Nature16997 |
0.617 |
|
| 2016 |
Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, et al. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. PMID 26934650 DOI: 10.18632/Oncotarget.7702 |
0.454 |
|
| 2016 |
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, et al. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. PMID 26864341 DOI: 10.1182/Blood-2015-11-681171 |
0.476 |
|
| 2016 |
Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, et al. BCOR regulates myeloid cell proliferation and differentiation. Leukemia. PMID 26847029 DOI: 10.1038/Leu.2016.2 |
0.667 |
|
| 2016 |
Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1, and MYC, and can be targeted by SYK inhibition. Leukemia. PMID 26847027 DOI: 10.1038/Leu.2016.9 |
0.585 |
|
| 2016 |
Hurtz C, Chan LN, Ballabio E, Willman CL, Carroll WL, Armstrong SA, Ernst P, Melnick A, Milne T, Müschen M. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia Blood. 128: 907-907. DOI: 10.1182/Blood.V128.22.907.907 |
0.576 |
|
| 2016 |
Chan LN, Hurtz C, Xiao G, Shojaee S, Caeser R, Geng H, Melnick A, Müschen M. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation Blood. 128: 438-438. DOI: 10.1182/Blood.V128.22.438.438 |
0.706 |
|
| 2016 |
Chan LN, Chen Z, Xiao G, Lee J, Geng H, Christian H, Cazzaniga V, Cazzaniga G, Dickins RA, Müschen M. Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation Blood. 128: 437-437. DOI: 10.1182/Blood.V128.22.437.437 |
0.553 |
|
| 2016 |
Lee J, Geng H, Chen Z, Klemm L, Cosgun KN, Xiao G, Masouleh B, Hurtz C, Parekh S, Kornblau SM, Melnick A, Abbas A, Paietta E, Müschen M. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies Blood. 128: 4088-4088. DOI: 10.1182/Blood.V128.22.4088.4088 |
0.555 |
|
| 2016 |
Teppo S, Mehtonen J, Eldfors S, Heckman CA, Müschen M, Heinäniemi M, Lohi O. Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments Blood. 128: 4077-4077. DOI: 10.1182/Blood.V128.22.4077.4077 |
0.302 |
|
| 2016 |
Chen Z, Geng H, Klemm L, Chan LN, Daniel B, Alexander WS, Willman CL, Müschen M. Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism Blood. 128: 4069-4069. DOI: 10.1182/Blood.V128.22.4069.4069 |
0.565 |
|
| 2016 |
Chan LN, Lee J, Cosgun KN, Geng H, Xiao G, Chen Z, Ernst T, Hochhaus A, Müschen M. Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia Blood. 128: 2771-2771. DOI: 10.1182/Blood.V128.22.2771.2771 |
0.631 |
|
| 2016 |
Gotesman M, Vo TT, Mallya S, Zhang Q, Shi C, Müschen M, Weinstock DM, Mullighan C, Tasian SK, Konopleva M, Fruman DA. mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL Blood. 128: 2763-2763. DOI: 10.1182/Blood.V128.22.2763.2763 |
0.475 |
|
| 2016 |
Lee J, Geng H, Cosgun KN, Chan LN, Chen Z, Park E, Klemm L, Bailey CC, Müschen M. IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies Blood. 128: 2738-2738. DOI: 10.1182/Blood.V128.22.2738.2738 |
0.532 |
|
| 2016 |
Xiao G, Chen Z, Daniel B, Chan LN, Geng H, Jiang X, Müschen M. PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia Blood. 128: 1056-1056. DOI: 10.1182/Blood.V128.22.1056.1056 |
0.647 |
|
| 2016 |
Chen Z, Geng H, Lowell CA, Hunger SP, Müschen M. Abstract PR11: Targeted engagement of B cell autoimmunity checkpoints to overcome drug resistance in pediatric Ph-like ALL Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr11 |
0.63 |
|
| 2016 |
Köhrer S, Seyfried F, Debatin K, Müschen M, Meyer L, Davis R, Burger J. Pre-BCR expression predicts sensitivity to SYK inhibition in B-cell acute lymphoblastic leukemia Klinische Padiatrie. 228. DOI: 10.1055/S-0036-1582492 |
0.531 |
|
| 2015 |
Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, et al. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports. 13: 2715-27. PMID 26711339 DOI: 10.1016/J.Celrep.2015.12.003 |
0.418 |
|
| 2015 |
Song C, Pan X, Ge Z, Gowda C, Ding Y, Li H, Li Z, Yochum G, Muschen M, Li Q, Payne KJ, Dovat S. Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II (CK2) in leukemia. Leukemia. PMID 26639180 DOI: 10.1038/Leu.2015.331 |
0.463 |
|
| 2015 |
Greaves M, Müschen M. Infection and the Perils of B-cell Activation. Cancer Discovery. 5: 1244-6. PMID 26637659 DOI: 10.1158/2159-8290.Cd-15-1243 |
0.529 |
|
| 2015 |
Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, et al. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. PMID 26324703 DOI: 10.1182/Blood-2015-04-639138 |
0.45 |
|
| 2015 |
Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH, Wang H, Muthusami S, Ge Z, Sachdev M, Amin SG, Desai D, Gowda K, Gowda R, Robertson GP, ... ... Muschen M, et al. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. Blood. PMID 26219304 DOI: 10.1182/Blood-2015-06-651505 |
0.477 |
|
| 2015 |
Swaminathan S, Müschen M. Infectious origins of childhood leukemia. Oncotarget. 6: 16798-9. PMID 26196452 DOI: 10.18632/Oncotarget.4630 |
0.74 |
|
| 2015 |
Shojaee S, Caeser R, Buchner M, Park E, Swaminathan S, Hurtz C, Geng H, Chan LN, Klemm L, Hofmann WK, Qiu YH, Zhang N, Coombes KR, Paietta E, Molkentin J, et al. Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer Cell. 28: 114-28. PMID 26073130 DOI: 10.1016/J.Ccell.2015.05.008 |
0.825 |
|
| 2015 |
Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon SM, Trageser D, Hasselfeld B, Henke N, Mooster J, Geng H, Schwarz K, Kogan SC, Casellas R, Schatz DG, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nature Immunology. 16: 766-74. PMID 25985233 DOI: 10.1038/Ni.3160 |
0.631 |
|
| 2015 |
Müschen M. Ph+ ALL: drawing strength from a benign past. Blood. 125: 2879-80. PMID 25953975 DOI: 10.1182/Blood-2015-03-632174 |
0.384 |
|
| 2015 |
Montamat-Sicotte D, Litzler LC, Abreu C, Safavi S, Zahn A, Orthwein A, Müschen M, Oppezzo P, Muñoz DP, Di Noia JM. HSP90 inhibitors decrease AID levels and activity in mice and in human cells. European Journal of Immunology. PMID 25912253 DOI: 10.1002/Eji.201545462 |
0.502 |
|
| 2015 |
Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8: 39. PMID 25895498 DOI: 10.1186/S13045-015-0132-6 |
0.395 |
|
| 2015 |
Müschen M. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Blood. 125: 3688-93. PMID 25878119 DOI: 10.1182/Blood-2015-01-567842 |
0.623 |
|
| 2015 |
Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 521: 357-61. PMID 25799995 DOI: 10.1038/Nature14231 |
0.764 |
|
| 2015 |
Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003 |
0.836 |
|
| 2015 |
Buchner M, Park E, Geng H, Klemm L, Flach J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P, Müschen M. Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature Communications. 6: 6471. PMID 25753524 DOI: 10.1038/Ncomms7471 |
0.594 |
|
| 2015 |
Buchner M, Swaminathan S, Chen Z, Müschen M. Mechanisms of pre-B-cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. Immunological Reviews. 263: 192-209. PMID 25510278 DOI: 10.1111/Imr.12235 |
0.743 |
|
| 2015 |
Gang X, Geng H, Chan LN, Chen Z, Jiang X, Muschen M. PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood. 126: 902-902. DOI: 10.1182/Blood.V126.23.902.902 |
0.672 |
|
| 2015 |
Li Q, Hurtz C, Shojaee S, Chen Z, Geng H, Xiao G, Loh ML, Ye BH, Melnick A, Muschen M. Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia Blood. 126: 556-556. DOI: 10.1182/Blood.V126.23.556.556 |
0.693 |
|
| 2015 |
Sullivan K, Bolton-Gillespie E, Nieborowska-Skorska M, Cerny-Reiterer S, Valent P, Muschen M, Pomerantz R, Mazin A, Skorski T. Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors Blood. 126: 50-50. DOI: 10.1182/Blood.V126.23.50.50 |
0.471 |
|
| 2015 |
Chen Z, Geng H, Lowell CA, Weiss A, Hunger SP, Melnick A, Muschen M. Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia Blood. 126: 3716-3716. DOI: 10.1182/Blood.V126.23.3716.3716 |
0.644 |
|
| 2015 |
Shi C, Han L, Zhang Q, Roberts KG, Park E, Tabe Y, Jacamo RO, Mu H, Wu S, Zhou J, Ma H, Zeng Z, Jain N, Jabbour EJ, Muschen M, et al. Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia Blood. 126: 2529-2529. DOI: 10.1182/Blood.V126.23.2529.2529 |
0.559 |
|
| 2015 |
Gang E, Hsieh Y, Kim HN, Duchartre Y, Stephanie S, Muschen M, Wayner E, Heisterkamp N, Bonig H, Kim Y. Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10 Blood. 126: 2525-2525. DOI: 10.1182/Blood.V126.23.2525.2525 |
0.407 |
|
| 2015 |
Deng R, Hurtz C, Yue C, Xiao G, Yu H, Muschen M, Forman SJ, Martin PJ, Zeng D. Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation Blood. 126: 1875-1875. DOI: 10.1182/Blood.V126.23.1875.1875 |
0.392 |
|
| 2015 |
Klemm L, Swaminathan S, Papaemmanuil E, Ford AM, Greaves M, Casellas R, Schatz D, Lieber MR, Muschen M. Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia Blood. 126: 166-166. DOI: 10.1182/Blood.V126.23.166.166 |
0.721 |
|
| 2015 |
Lee J, Chen Z, Geng H, Xiao G, PARK E, Parekh S, Kornblau SM, Melnick A, Abbas A, Paietta E, Muschen M. CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia Blood. 126: 1434-1434. DOI: 10.1182/Blood.V126.23.1434.1434 |
0.524 |
|
| 2015 |
Lee J, Geng H, Chen Z, Park E, Klemm L, Bailey CC, Muschen M. IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells Blood. 126: 1325-1325. DOI: 10.1182/Blood.V126.23.1325.1325 |
0.524 |
|
| 2015 |
Chan LN, Chen Z, Braas D, Geng H, Hurtz C, Shojaee S, Cazzaniga V, Ng C, Ernst T, Hochhaus A, Kornblau SM, Cazzaniga G, Liu G, Milne T, Koeffler HP, ... ... Muschen M, et al. B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling Blood. 126: 1255-1255. DOI: 10.1182/Blood.V126.23.1255.1255 |
0.741 |
|
| 2015 |
Cao Q, Zhao X, Gery S, Chen Z, Deng R, Sun H, Lin D, Zhao Z, Said JW, Li Q, Muschen M, Evans RM, Koeffler HP. Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance Blood. 126: 1029-1029. DOI: 10.1182/Blood.V126.23.1029.1029 |
0.52 |
|
| 2015 |
Chen Y, Xu L, Hazawa M, Thippeswamy AM, Yang H, Müschen M, Lin D, Koeffler P. Abstract 4944: Identification of B-cell lymphoma 6 as a novel therapeutic target in glioblastoma Cancer Research. 75: 4944-4944. DOI: 10.1158/1538-7445.Am2015-4944 |
0.59 |
|
| 2015 |
Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Loh ML, Jung JU, Coligan JE, Bolland S, et al. Abstract 2075: Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia Cancer Research. 75: 2075-2075. DOI: 10.1158/1538-7445.Am2015-2075 |
0.763 |
|
| 2014 |
Swaminathan S, Müschen M. Follicular lymphoma: too many reminders for a memory B cell. The Journal of Clinical Investigation. 124: 5095-8. PMID 25384212 DOI: 10.1172/Jci79189 |
0.705 |
|
| 2014 |
Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK. Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. Scientific Reports. 4: 6565. PMID 25298122 DOI: 10.1038/Srep06565 |
0.488 |
|
| 2014 |
Buchner M, Müschen M. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Current Opinion in Hematology. 21: 341-9. PMID 24811161 DOI: 10.1097/Moh.0000000000000048 |
0.627 |
|
| 2014 |
Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L, Müschen M, Chen CC. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget. 5: 211-23. PMID 24457556 DOI: 10.18632/Oncotarget.1319 |
0.422 |
|
| 2014 |
Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, van Delft FW, Nik-Zainal S, ... ... Muschen M, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nature Genetics. 46: 116-25. PMID 24413735 DOI: 10.1038/Ng.2874 |
0.456 |
|
| 2014 |
Swaminathan S, Klemm L, Park E, Ford AM, Kweon S, Trageser D, Hasselfeld B, Henke N, Geng H, Schwarz K, Casellas R, Schatz DG, Lieber MR, Papaemmanuil E, Greaves M, ... Muschen M, et al. Mechanisms of Clonal Evolution of Pre-Leukemic Clones in Childhood Pre-B Acute Lymphoblastic Leukemia Blood. 124: 861-861. DOI: 10.1182/Blood.V124.21.861.861 |
0.749 |
|
| 2014 |
Chen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell CA, Paietta E, Willman CL, Carroll WL, Melnick A, Jung JU, Jumaa H, Coligan JE, Bolland S, ... ... Muschen M, et al. Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia Blood. 124: 792-792. DOI: 10.1182/Blood.V124.21.792.792 |
0.753 |
|
| 2014 |
Buchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Muschen M. FOXM1 Mediates Drug-Resistance and Represents a Therapeutic Target in Pre-B Acute Lymphoblastic Leukemia Blood. 124: 790-790. DOI: 10.1182/Blood.V124.21.790.790 |
0.666 |
|
| 2014 |
Geng H, Lee J, Chen Z, Kharabi Masouleh B, Hurtz C, Park E, Xiao G, Parekh S, Kornblau SM, Melnick A, Paietta E, Muschen M. IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia Blood. 124: 788-788. DOI: 10.1182/Blood.V124.21.788.788 |
0.505 |
|
| 2014 |
Seyedmehdi S, Chen Z, Buchner M, Hurtz C, Geng H, Schjerven H, Chan LN, Koeffler P, Willman CL, Hunger S, Dovat S, Paietta E, Hofmann W, Melnick AM, Alexander WS, ... ... Muschen M, et al. Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia Blood. 124: 787-787. DOI: 10.1182/Blood.V124.21.787.787 |
0.633 |
|
| 2014 |
Chan LN, Braas D, Hurtz C, Shojaee S, Kharabi Masouleh B, Geng H, Ernst T, Hochhaus A, Graeber T, Muschen M. Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia Blood. 124: 783-783. DOI: 10.1182/Blood.V124.21.783.783 |
0.729 |
|
| 2014 |
Park E, Swaminathan S, Sadiyah MF, Igarashi K, Melnick A, Muschen M. BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia Blood. 124: 513-513. DOI: 10.1182/Blood.V124.21.513.513 |
0.747 |
|
| 2014 |
Nieborowska-Skorska M, Sullivan K, Podszywalow-Bartnicka P, Hoser G, Bolton-Gillespie E, Cramer-Morales K, Slupianek A, Zhou C, Cerny-Reiterer S, Stoklosa T, Sykes SM, Valent P, Civin CI, Muschen M, Minden MD, et al. Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells Blood. 124: 480-480. DOI: 10.1182/Blood.V124.21.480.480 |
0.427 |
|
| 2014 |
Lee J, Buchner M, Geng H, Swaminathan S, Park E, Park A, Lin-Chao S, So CW, Muschen M. The Linker Protein GAS7 Negatively Regulates Pre-B Cell Differentiation and Amplifies Proliferation and Survival Signals in Acute Lymphoblastic Leukemia Blood. 124: 3777-3777. DOI: 10.1182/Blood.V124.21.3777.3777 |
0.797 |
|
| 2014 |
Hurtz C, Geng H, Xiao G, Loh ML, Ye BH, Melnick A, Muschen M. BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia Blood. 124: 3570-3570. DOI: 10.1182/Blood.V124.21.3570.3570 |
0.604 |
|
| 2014 |
Xiao G, Geng H, Chan LN, Chen Z, Muschen M. Divergent Lineage-Specific Functions of PP2A in Chronic Phase CML and Lymphoid Blast Crisis Blood. 124: 3128-3128. DOI: 10.1182/Blood.V124.21.3128.3128 |
0.657 |
|
| 2014 |
Geng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee J, Deucher A, Qi Z, Huang C, Nahar R, Kweon S, Shojaee S, Chan LN, ... ... Muschen M, et al. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia Blood. 124: 284-284. DOI: 10.1182/Blood.V124.21.284.284 |
0.867 |
|
| 2014 |
Shojaee S, Cazzaniga V, Schjerven H, Buchner M, Hurtz C, Geng H, Hochhaus A, Cazzaniga G, Melnick AM, Kornblau SM, Graeber TG, Muschen M. PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells Blood. 124: 262-262. DOI: 10.1182/Blood.V124.21.262.262 |
0.796 |
|
| 2014 |
Lee J, Geng H, Chen Z, Park E, Park A, Klemm L, Bailey C, Muschen M. IFITM3 (CD225) Regulates CD19 Surface Expression and CD19-Mediated Activation of PI3K Signaling in Pre-B Acute Lymphoblastic Leukemia Cells Blood. 124: 1070-1070. DOI: 10.1182/Blood.V124.21.1070.1070 |
0.524 |
|
| 2014 |
Shojaee S, Muschen M. Biology and targeting options for kinase signaling in acute lymphoblastic leukemia Aacr Education Book. 2014: 91-94. DOI: 10.1158/Aacr.Edb-14-1332 |
0.605 |
|
| 2014 |
Sun H, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Masouleh K, Müschen M, Koeffler HP. Abstract 510: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia Cancer Research. 74: 510-510. DOI: 10.1158/1538-7445.Am2014-510 |
0.468 |
|
| 2014 |
Buchner MV, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Müschen M. Abstract 484: Identification of FOXM1 as therapeutic target in Philadelphia chromosome-positive acute lymphoblastic leukemia Cancer Research. 74: 484-484. DOI: 10.1158/1538-7445.Am2014-484 |
0.597 |
|
| 2014 |
Chan LN, Shojaee S, Hurtz C, Geng H, Ng C, Kharabi B, Müschen M. Abstract 2447: Lineage-specific metabolic reprogramming in BCR-ABL1-driven leukemia Cancer Research. 74: 2447-2447. DOI: 10.1158/1538-7445.Am2014-2447 |
0.73 |
|
| 2013 |
Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia. The Journal of Experimental Medicine. 210: 805-19. PMID 23478187 DOI: 10.1084/Jem.20121482 |
0.401 |
|
| 2013 |
Cui X, Lu Z, Kurosawa A, Klemm L, Bagshaw AT, Tsai AG, Gemmell N, Müschen M, Adachi N, Hsieh CL, Lieber MR. Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation. Molecular and Cellular Biology. 33: 947-57. PMID 23263985 DOI: 10.1128/Mcb.01436-12 |
0.318 |
|
| 2013 |
Ramezani-Rad P, Geng H, Hurtz C, Chan LN, Chen Z, Jumaa H, Melnick A, Paietta E, Carroll WL, Willman CL, Lefebvre V, Müschen M. SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 121: 148-55. PMID 23152540 DOI: 10.1182/Blood-2012-05-428938 |
0.539 |
|
| 2013 |
Masouleh BK, Geng H, Hurtz C, Huang C, Chan LN, Swaminathan S, Sun H, Koeffler HP, Melnick A, Paietta E, Glimcher LH, Muschen M. The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL Blood. 122: 836-836. DOI: 10.1182/Blood.V122.21.836.836 |
0.742 |
|
| 2013 |
Nieborowska-Skorska M, Slupianek A, Hoser G, Bolton-Gillespie E, Tulin A, Cerny-Reiterer S, Valent P, Muschen M, Sykes SM, Skorski T. Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells Blood. 122: 810-810. DOI: 10.1182/Blood.V122.21.810.810 |
0.538 |
|
| 2013 |
Hurtz C, Geng H, Ballabio E, Xiao G, Ng C, Masouleh BK, Willman CL, Armstrong SA, Milne T, Melnick A, Muschen M. Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL Blood. 122: 72-72. DOI: 10.1182/Blood.V122.21.72.72 |
0.568 |
|
| 2013 |
Konopleva M, Benito JM, Harutyunyan KG, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo R, Park E, Muschen M, Mulloy JC, Bendall LJ, Zweidler-McKay PA, Coombes KR, Qiu Y, et al. Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199 Blood. 122: 3919-3919. DOI: 10.1182/Blood.V122.21.3919.3919 |
0.471 |
|
| 2013 |
Geng H, Hurtz C, Chen Z, Chen W, Ballabio E, Xiao G, Kweon S, Nahar R, Sojaee S, Chan LN, Masouleh BK, Sykes DB, Melnick A, Roeder R, Milne T, ... Muschen M, et al. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia Blood. 122: 349-349. DOI: 10.1182/Blood.V122.21.349.349 |
0.834 |
|
| 2013 |
Buchner M, Geng H, Swaminathan S, Park E, Klemm L, Lin-Chao S, So CW, Muschen M. Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells Blood. 122: 2506-2506. DOI: 10.1182/Blood.V122.21.2506.2506 |
0.75 |
|
| 2013 |
Geng H, Chen Z, Park E, Klemm L, Bailey CC, Muschen M. Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL Blood. 122: 2505-2505. DOI: 10.1182/Blood.V122.21.2505.2505 |
0.575 |
|
| 2013 |
Chen Z, Shojaee S, Geng H, Lee J, Buchner M, Klemm L, Lowell CA, Paietta E, Willman CL, Carroll WL, Melnick AM, Jung JU, Jumaa H, Coligan JE, Bolland S, ... ... Muschen M, et al. Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia Blood. 122: 229-229. DOI: 10.1182/Blood.V122.21.229.229 |
0.766 |
|
| 2013 |
Dasgupta Y, Koptyra M, Nieborowska-Skorska M, Gillespie EB, Stoklosa T, Hoser G, Wasik M, Muschen M, Richardson C, Skorski T. Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1–positive Leukemias Blood. 122: 1466-1466. DOI: 10.1182/Blood.V122.21.1466.1466 |
0.588 |
|
| 2013 |
Pan R, Debose L, Benito JM, Golfman LS, Zweidler-McKay PA, Han L, Harutyunyan KG, Mu H, Ruvolo VR, Park E, Muschen M, Leverson J, Borthakur G, Kantarjian HM, Ruvolo PP, et al. BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia Blood. 122: 1456-1456. DOI: 10.1182/Blood.V122.21.1456.1456 |
0.493 |
|
| 2013 |
Kim E, Koehrer S, Rosin NY, Wang Z, Thomas DA, Ravandi F, Kornblau SM, Kantarjian HM, O'Brien S, Estrov Z, Buggy JJ, Muschen M, Davis RE, Burger JA. Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia Blood. 122: 1399-1399. DOI: 10.1182/Blood.V122.21.1399.1399 |
0.655 |
|
| 2013 |
Buchner M, Park E, Klemm L, Geng H, Kopanja D, Raychaudhuri P, Muschen M. Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia Blood. 122: 1250-1250. DOI: 10.1182/Blood.V122.21.1250.1250 |
0.606 |
|
| 2013 |
Silveira V, Shojaee S, Müschen M. Abstract A55: Induced hyperactivation of Ras-MAPK in chronic myeloid leukemia: role of negative feedback signaling Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-A55 |
0.703 |
|
| 2013 |
Shojaee S, Buchner M, Gery S, Geng H, Chan LN, Melnick A, Koeffler PH, Müschen M. Abstract 2334: Targeting inhibitory phosphatase signaling in Ph+ ALL. Cancer Research. 73: 2334-2334. DOI: 10.1158/1538-7445.Am2013-2334 |
0.724 |
|
| 2012 |
Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 22: 656-67. PMID 23153538 DOI: 10.1016/J.Ccr.2012.08.027 |
0.594 |
|
| 2012 |
Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. Plos One. 7: e40934. PMID 22848414 DOI: 10.1371/Journal.Pone.0040934 |
0.517 |
|
| 2012 |
Chang BH, Jemal A, Tyner J, Thayer M, Muschen M, Druker BJ. YM155 sensitivity in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology. 30: 9555-9555. DOI: 10.1200/Jco.2012.30.15_Suppl.9555 |
0.412 |
|
| 2012 |
Buchner M, Klemm L, Zhengshan C, Geng H, Muschen M. Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL Blood. 120: 874-874. DOI: 10.1182/Blood.V120.21.874.874 |
0.541 |
|
| 2012 |
Masouleh BK, Hurtz C, Geng H, Ramezani-Rad P, Glimcher LH, Muschen M. Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL Blood. 120: 872-872. DOI: 10.1182/Blood.V120.21.872.872 |
0.572 |
|
| 2012 |
Hurtz C, Ramezani-Rad P, Geng H, Kharabi B, Carroll WL, Willman CL, Armstrong SA, Melnick A, Muschen M. Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL Blood. 120: 776-776. DOI: 10.1182/Blood.V120.21.776.776 |
0.559 |
|
| 2012 |
Geng H, Nahar R, Ramezani-Rad P, Chen Z, Tyner JW, Chang BH, Titz B, Buchner M, Hurtz C, Graeber TG, Druker BJ, Paietta E, Melnick A, Willman CL, Carroll WL, ... Muschen M, et al. Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL Blood. 120: 528-528. DOI: 10.1182/Blood.V120.21.528.528 |
0.531 |
|
| 2012 |
Swaminathan S, Klemm L, Ford AM, Schwarz K, Casellas R, Hennighausen L, Geng H, Schatz DG, Lieber MR, Greaves M, Muschen M. Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia Blood. 120: 519-519. DOI: 10.1182/Blood.V120.21.519.519 |
0.759 |
|
| 2012 |
Cao Q, Gery S, Shojaee S, Gearhart M, Bardwell V, Muschen M, Koeffler HP. BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes Blood. 120: 3445-3445. DOI: 10.1182/Blood.V120.21.3445.3445 |
0.703 |
|
| 2012 |
Chan LN, Geng H, Muschen M. Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis Blood. 120: 34-34. DOI: 10.1182/Blood.V120.21.34.34 |
0.643 |
|
| 2012 |
Chen Z, Geng H, Buchner M, Klemm L, Hemati K, Shojaee S, Tak MW, Coligan JE, Carroll WL, Willman CL, Muschen M. ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL Blood. 120: 291-291. DOI: 10.1182/Blood.V120.21.291.291 |
0.718 |
|
| 2012 |
Gang EJ, Hsieh Y, Geng H, Pham J, Muschen M, Arcangelis Ad, Willman CL, Carroll WL, Georges-Labouesse E, Bonig H, Kim Y. Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia. Blood. 120: 2565-2565. DOI: 10.1182/Blood.V120.21.2565.2565 |
0.585 |
|
| 2012 |
Chen Z, Geng H, Klemm L, Buchner M, Hemati K, Shojaee S, Alexander WS, Carroll WL, Willman CL, Muschen M. Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood. 120: 2563-2563. DOI: 10.1182/Blood.V120.21.2563.2563 |
0.74 |
|
| 2012 |
Shojaee S, Buchner M, Swaminathan S, Geng H, Chan L, Bothe M, Chen Z, Melnick A, Molkentin J, Martin G, Koeffler HP, Muschen M. Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases Blood. 120: 1352-1352. DOI: 10.1182/Blood.V120.21.1352.1352 |
0.789 |
|
| 2012 |
Shojaee S, Geng H, Gearhart M, Bardwell V, Muschen M. BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia Blood. 120: 1301-1301. DOI: 10.1182/Blood.V120.21.1301.1301 |
0.719 |
|
| 2012 |
Swaminathan S, Kang H, Harvey RC, Huang C, Buchner M, Chen Z, Geng H, Hall A, Igarashi K, Carroll WL, Willman CL, Melnick A, Muschen M. BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance Blood. 120: 1300-1300. DOI: 10.1182/Blood.V120.21.1300.1300 |
0.765 |
|
| 2012 |
Shojaee S, Buchner M, Swaminathan S, Chan L, Bothe M, Geng H, Melnick A, Molkentin J, Martin G, Koeffler P, Muschen M. Abstract 2944: Targeting negative feedback signaling in tyrosine kinase-driven malignancies Cancer Research. 72: 2944-2944. DOI: 10.1158/1538-7445.Am2012-2944 |
0.733 |
|
| 2011 |
Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 118: 4174-8. PMID 21856866 DOI: 10.1182/Blood-2011-01-331181 |
0.835 |
|
| 2011 |
Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3219-32. PMID 21474579 DOI: 10.1158/1078-0432.Ccr-11-0234 |
0.514 |
|
| 2011 |
Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Science Signaling. 4: ra18. PMID 21447799 DOI: 10.1126/Scisignal.2001314 |
0.427 |
|
| 2011 |
Thai M, Ting PY, McLaughlin J, Cheng D, Müschen M, Witte ON, Colicelli J. ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 25: 290-300. PMID 21102429 DOI: 10.1038/Leu.2010.268 |
0.464 |
|
| 2011 |
Klemm L, Swaminathan S, Ford AM, Schwarz K, Schatz DG, Lieber MR, Greaves MF, Muschen M. Infectious Origins of Childhood Leukemia Blood. 118: 751-751. DOI: 10.1182/Blood.V118.21.751.751 |
0.764 |
|
| 2011 |
Swaminathan S, Huang C, Titz B, Buchner M, Geng H, Graeber TG, Willman CL, Igarashi K, Melnick A, Muschen M. BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia Blood. 118: 562-562. DOI: 10.1182/Blood.V118.21.562.562 |
0.771 |
|
| 2011 |
Hurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller MC, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker BJ, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood. 118: 446-446. DOI: 10.1182/Blood.V118.21.446.446 |
0.547 |
|
| 2011 |
Nahar R, Ramezani-Rad P, Dovat S, Buchner M, Graeber TG, Muschen M. Mechanisms of Ikaros-Mediated Tumor Suppression Blood. 118: 408-408. DOI: 10.1182/Blood.V118.21.408.408 |
0.835 |
|
| 2011 |
Jemal A, Tyner JW, Thayer M, Muschen M, Druker BJ, Chang BH. Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia Blood. 118: 2490-2490. DOI: 10.1182/Blood.V118.21.2490.2490 |
0.5 |
|
| 2011 |
Bicocca VT, Chang BH, Muschen M, Druker BJ, Tyner JW. Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia Blood. 118: 2466-2466. DOI: 10.1182/Blood.V118.21.2466.2466 |
0.541 |
|
| 2011 |
Shojaee S, Buchner M, Geng H, Melnick A, Gery S, Molkentin J, Koeffler P, Muschen M. DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival Blood. 118: 1479-1479. DOI: 10.1182/Blood.V118.21.1479.1479 |
0.754 |
|
| 2011 |
Shojaee S, Buchner M, Geng H, Silvia B, Koeffler P, Muschen M. Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias Blood. 118: 1382-1382. DOI: 10.1182/Blood.V118.21.1382.1382 |
0.715 |
|
| 2011 |
Rubbi L, Titz B, Brown L, Glavan E, Komisopoulou E, Chen SS, Low T, Tahmasian M, Skaggs B, Müschen M, Pellegrini M, Graeber TG. Abstract LB-25: Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-25 |
0.425 |
|
| 2011 |
Duy C, Hurtz C, Koeffler PH, Melnick AM, Müschen M. Abstract LB-235: BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-235 |
0.54 |
|
| 2011 |
Nguyen TK, Attkisson E, Dai Y, Kramer L, Muschen M, Grant S. Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cellsin vitroandin vivo Cancer Research. 71: 2572-2572. DOI: 10.1158/1538-7445.Am2011-2572 |
0.499 |
|
| 2010 |
Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Research. 70: 4346-56. PMID 20460528 DOI: 10.1158/0008-5472.Can-10-0300 |
0.611 |
|
| 2010 |
Fei F, Stoddart S, Müschen M, Kim Y, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia Leukemia. 24: 813-820. PMID 20111071 DOI: 10.1038/Leu.2009.302 |
0.498 |
|
| 2010 |
Wang XM, Greiner TC, Bibikova M, Pike BL, Siegmund KD, Sinha UK, Müschen M, Jaeger EB, Weisenburger DD, Chan WC, Shibata D, Fan JB, Hacia JG. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. Journal of Cellular Biochemistry. 109: 818-27. PMID 20069569 DOI: 10.1002/Jcb.22461 |
0.388 |
|
| 2010 |
Hsieh Y, Park E, Jiang E, Dauber K, Chudziak D, Schaefer P, Klemm L, Scharman C, Kang E, Koo H, Loh ML, Hofmann WK, Heisterkamp N, Muschen M, Shimada H, et al. Adjuvant CD49d Blockade Eradicates Chemoresistant ALL Blood. 116: 869-869. DOI: 10.1182/Blood.V116.21.869.869 |
0.53 |
|
| 2010 |
Bicocca V, Chang BH, Muschen M, Druker BJ, Tyner JW. ROR1 as a Therapeutic Target In E2A-PBX1-Positive Acute Lymphoblastic Leukemia Blood. 116: 539-539. DOI: 10.1182/Blood.V116.21.539.539 |
0.53 |
|
| 2010 |
Shojaee S, Garcia C, Wu H, Muschen M. The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid Leukemia Blood. 116: 513-513. DOI: 10.1182/Blood.V116.21.513.513 |
0.782 |
|
| 2010 |
Ng C, Nahar R, Elliott E, Lowell CA, Muschen M. SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target Blood. 116: 4199-4199. DOI: 10.1182/Blood.V116.21.4199.4199 |
0.852 |
|
| 2010 |
Jiang E, Park E, Nguyen C, Yoon J, Hsieh Y, Loh ML, Muschen M, Kahn M, Kim Y. Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin Blood. 116: 3264-3264. DOI: 10.1182/Blood.V116.21.3264.3264 |
0.457 |
|
| 2010 |
Park E, Jiang E, Hsieh Y, Klemm L, Duy C, Conway EM, Pelus LM, Crispino J, Loh ML, Kang E, Koo H, Yang A, Heisterkamp N, Kahn M, Muschen M, et al. Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia Blood. 116: 3263-3263. DOI: 10.1182/Blood.V116.21.3263.3263 |
0.485 |
|
| 2010 |
Iwanski GB, Thoennissen NH, Nakitandwe J, Lin P, Kawamata N, Nahar R, Ramezani-Rad P, Chen S, Shurtleff S, Nowak D, Ruckert C, Dugas M, Bokemeyer C, Fazio G, Biondi A, et al. Dominant-Negative Impact of PAX5/TEL on Downstream Targets of PAX5 and Essential Pre-B Cell Receptor Genes Blood. 116: 3231-3231. DOI: 10.1182/Blood.V116.21.3231.3231 |
0.553 |
|
| 2010 |
Nahar R, Trageser D, Klemm L, Duy C, Hofmann W, Park E, Kim Y, Heisterkamp N, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia Blood. 116: 274-274. DOI: 10.1182/Blood.V116.21.274.274 |
0.844 |
|
| 2010 |
Miles RR, Downie J, Jahromi MS, Joshi D, Rodic V, Muschen M, Yang JJ, Evans WE, Meeker N, Trede N, Frazer JK, Barnette P, Schiffman JD. VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL) Blood. 116: 273-273. DOI: 10.1182/Blood.V116.21.273.273 |
0.519 |
|
| 2010 |
Swaminathan S, Klemm L, Kweon S, Ford A, Schwarz K, Casellas R, Hennighausen L, Schatz DG, Lieber MR, Greaves MF, Muschen M. IL7Rα Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia Blood. 116: 26-26. DOI: 10.1182/Blood.V116.21.26.26 |
0.771 |
|
| 2010 |
Hurtz C, Duy C, Cerchietti L, Chatzi K, Park E, Klemm L, Kim Y, Kahn M, Braig M, Muller MC, Hochhaus A, Ye BH, Melnick AM, Muschen M. BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia Blood. 116: 202-202. DOI: 10.1182/Blood.V116.21.202.202 |
0.593 |
|
| 2010 |
Duy C, Nowak D, Klemm L, Nahar R, Ng C, Elliott E, Hofmann W, Heisterkamp N, Lowell CA, Koeffler P, Muschen M. Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia Blood. 116: 147-147. DOI: 10.1182/Blood.V116.21.147.147 |
0.851 |
|
| 2010 |
Nahar R, Ramezani-Rad P, Duy C, Dovat S, Ye BH, Melnick AM, Muschen M. IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor Blood. 116: 146-146. DOI: 10.1182/Blood.V116.21.146.146 |
0.85 |
|
| 2009 |
Nahar R, Müschen M. Pre-B cell receptor signaling in acute lymphoblastic leukemia. Cell Cycle (Georgetown, Tex.). 8: 3874-7. PMID 19901533 DOI: 10.4161/Cc.8.23.10035 |
0.836 |
|
| 2009 |
Iacobucci I, Messina M, Iraci N, Lonetti A, Chiaretti S, Ferrari A, Papayannidis C, Messa F, Vitale A, Paoloni F, Cilloni D, Storlazzi CT, Ottaviani E, Paolini S, Durante S, ... ... Muschen M, et al. IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. Blood. 114: 912-912. DOI: 10.1182/Blood.V114.22.912.912 |
0.489 |
|
| 2009 |
Duy C, Yu JJ, Swaminathan S, Nahar RR, Kweon S, Polo JM, Valls E, Klemm L, Cerchietti L, Levetzow Gv, Herzog S, Jumaa H, Alborán IMd, Melnick A, Ye BH, et al. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood. 114: 91-91. DOI: 10.1182/Blood.V114.22.91.91 |
0.852 |
|
| 2009 |
Duy C, Cerchietti L, Yu JJ, Ci W, Swaminathan S, Nahar RR, Kweon S, Klemm L, Ye BH, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 765-765. DOI: 10.1182/Blood.V114.22.765.765 |
0.83 |
|
| 2009 |
Duy C, Sprangers M, Klemm L, Nahar RR, Nowak D, Martinelli G, Hofmann W, Koeffler PH, Jumaa H, Müschen M. Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 579-579. DOI: 10.1182/Blood.V114.22.579.579 |
0.815 |
|
| 2009 |
Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Muschen M, Sumerle L, Papayannidis C, Soverini S, Ottaviani E, Paolini S, Ferrari A, Messa F, Cilloni D, Vitale A, et al. Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with “Next Generation Sequencing” Technology Revealed Novel Point Mutations Associated with Disease-Progression. Blood. 114: 3074-3074. DOI: 10.1182/Blood.V114.22.3074.3074 |
0.39 |
|
| 2009 |
Jiang E, Park E, Scharman C, Hsieh Y, Kadavallore A, Nguyen C, Zhao Y, McMillan M, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia. Blood. 114: 3072-3072. DOI: 10.1182/Blood.V114.22.3072.3072 |
0.454 |
|
| 2009 |
Hurtz C, Duy C, Cerchietti L, Park E, Ci W, Swaminathan S, Kweon S, Klemm L, Kim Y, Martinelli G, Hofmann W, Ye BH, Melnick A, Müschen M. BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia. Blood. 114: 2167-2167. DOI: 10.1182/Blood.V114.22.2167.2167 |
0.717 |
|
| 2009 |
Chang MS, Wey S, Lee A, Müschen M. Inducible Ablation of HSPA5 Suppresses BCR-ABL1-Driven Leukemia through Massive Accumulation of Reactive Oxygen Species. Blood. 114: 1976-1976. DOI: 10.1182/Blood.V114.22.1976.1976 |
0.445 |
|
| 2009 |
Gruber T, Chang MS, Sposto R, Müschen M. Activation-Induced Cytidine Deaminase Accelerates Clonal Evolution of BCR-ABL1 -Driven B Cell Lineage Acute Lymphoblastic Leukemia. Blood. 114: 181-181. DOI: 10.1182/Blood.V114.22.181.181 |
0.471 |
|
| 2009 |
Nowak D, Kawamata N, Niebuhr B, Nowak V, Mossner M, Nahar RR, Thoennissen NH, Iwanski GB, Stocking C, Dugas M, Hofmann WK, Müschen M, Koeffler PH. The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines. Blood. 114: 1284-1284. DOI: 10.1182/Blood.V114.22.1284.1284 |
0.831 |
|
| 2009 |
Iacobucci I, Papayannidis C, Paoloni F, Lonetti A, Muschen M, Vignetti M, Cilloni D, Soverini S, Messa F, Paolini S, Chiaretti S, Guadagnuolo V, Fazi P, Vitale A, Meloni G, et al. PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party. Blood. 114: 12-12. DOI: 10.1182/Blood.V114.22.12.12 |
0.342 |
|
| 2009 |
Park E, Jiang E, Levetzow Gv, Duy C, Klemm L, Hsieh Y, Kadavallore A, Ma H, Zhao Y, Nguyen C, Groffen J, Heisterkamp N, Muschen M, Kahn M, Kim Y. Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia. Blood. 114: 10-10. DOI: 10.1182/Blood.V114.22.10.10 |
0.578 |
|
| 2008 |
Tsai AG, Lu H, Raghavan SC, Muschen M, Hsieh CL, Lieber MR. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell. 135: 1130-42. PMID 19070581 DOI: 10.1016/J.Cell.2008.10.035 |
0.441 |
|
| 2008 |
Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, Soverini S, Saglio G, Pane F, et al. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica. 93: 1814-21. PMID 18838475 DOI: 10.3324/Haematol.13260 |
0.329 |
|
| 2008 |
Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, Roosta N, Hescheler J, Müschen M. The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biological Chemistry. 389: 897-903. PMID 18681827 DOI: 10.1515/Bc.2008.108 |
0.491 |
|
| 2008 |
Müschen M. Highlight: self-renewal signaling in stem cells. Biological Chemistry. 389: 787. PMID 18681824 DOI: 10.1515/Bc.2008.090 |
0.354 |
|
| 2008 |
Klemm L, Duy C, Feldhahn N, Groffen J, Kim Y, Hofmann W, Jumaa H, Lieber MR, Casellas R, Muschen M. Lymphoid Blast Crisis Transformation and Development of Drug- Resistance in Chronic Myeloid Leukemia Are Driven by Aberrant Somatic Hypermutation Blood. 112: 571-571. DOI: 10.1182/Blood.V112.11.571.571 |
0.617 |
|
| 2008 |
Duy C, Klemm L, Nahar R, Essen Pv, Sprangers M, Kim Y, Park E, Martinelli G, Heisterkamp N, Hofmann W, Jumaa H, Muschen M. Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor Blood. 112: 294-294. DOI: 10.1182/Blood.V112.11.294.294 |
0.845 |
|
| 2008 |
Jiang E, Yu M, Hsieh Y, DeLaTorre B, Kadavallore A, Scharman C, Park E, Yang AS, Muschen M, Groffen J, Heisterkamp N, Kim Y. Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL Blood. 112: 2922-2922. DOI: 10.1182/Blood.V112.11.2922.2922 |
0.479 |
|
| 2008 |
Nahar R, Trageser D, Klemm L, Duy C, Essen Pv, Kim Y, Heisterkamp N, Martinelli G, Hofmann W, Jack H, Jumaa H, Muschen M. The Pre-B Cell Receptor Suppresses Leukemogenesis by Censoring MYC Expression. Blood. 112: 1918-1918. DOI: 10.1182/Blood.V112.11.1918.1918 |
0.641 |
|
| 2007 |
Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Molecular Cancer. 6: 67. PMID 17958915 DOI: 10.1186/1476-4598-6-67 |
0.408 |
|
| 2007 |
Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. The Journal of Experimental Medicine. 204: 1157-66. PMID 17485517 DOI: 10.1084/Jem.20062662 |
0.51 |
|
| 2007 |
Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 26: 323-33. PMID 17331747 DOI: 10.1016/J.Immuni.2007.01.012 |
0.525 |
|
| 2007 |
Duy C, Alboran IMd, Jumaa H, Muschen M. The Balance between Myc and Bcl6 Determines Self-Renewal or Differentiation of Pre-B Cells. Blood. 110: 797-797. DOI: 10.1182/Blood.V110.11.797.797 |
0.635 |
|
| 2007 |
Kim Y, Park E, Lorentzen C, Torre BDL, Hsieh Y, Whang H, Klemm L, Nguyen C, McMillan M, Teo J, Muschen M, Kahn M. Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia. Blood. 110: 1596-1596. DOI: 10.1182/Blood.V110.11.1596.1596 |
0.396 |
|
| 2007 |
Klemm L, Feldhahn N, Hoffmann TK, Hofmann W, Jumaa H, Muschen M. PAX5-Mediated Lineage Conversion and Expression of AID Accelerates Clonal Evolution and Initiates Darwinian Selection of BCR-ABL1-Mutants in Chronic Myeloid Leukemia. Blood. 110: 1005-1005. DOI: 10.1182/Blood.V110.11.1005.1005 |
0.55 |
|
| 2006 |
Sprangers M, Feldhahn N, Liedtke S, Jumaa H, Siebert R, Müschen M. SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells Oncogene. 25: 5180-5186. PMID 16636677 DOI: 10.1038/Sj.Onc.1209520 |
0.577 |
|
| 2006 |
Sprangers M, Feldhahn N, Herzog S, Hansmann M-, Reppel M, Hescheler J, Jumaa H, Siebert R, Müschen M. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells Oncogene. 25: 5056-5062. PMID 16568084 DOI: 10.1038/Sj.Onc.1209510 |
0.643 |
|
| 2006 |
Klapper W, Szczepanowski M, Heidorn K, Müschen M, Liedtke S, Sotnikova A, Andersen N, Greeve J, Parwaresch R. Immunoglobulin class-switch recombination occurs in mantle cell lymphomas. The Journal of Pathology. 209: 250-257. PMID 16508921 DOI: 10.1002/Path.1961 |
0.543 |
|
| 2006 |
Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene. 25: 1118-1124. PMID 16205638 DOI: 10.1038/Sj.Onc.1209133 |
0.638 |
|
| 2005 |
Feldhahn N, Río P, Soh BN, Liedtke S, Sprangers M, Klein F, Wernet P, Jumaa H, Hofmann WK, Hanenberg H, Rowley JD, Müschen M. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 13266-71. PMID 16141323 DOI: 10.1073/Pnas.0505196102 |
0.644 |
|
| 2005 |
Soh BN, Klein F, Feldhahn N, Müschen M. B-lymphoid or myeloid lineage identity of cell lines derived from chronic myeloid leukemia blast crisis. Cancer Genetics and Cytogenetics. 161: 187-8. PMID 16102593 DOI: 10.1016/J.Cancergencyto.2005.02.016 |
0.621 |
|
| 2005 |
Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, Wartenberg M, Bekhite MM, Hofmann WK, Herzog S, Jumaa H, Rowley JD, Müschen M. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. The Journal of Experimental Medicine. 201: 1837-52. PMID 15939795 DOI: 10.1084/Jem.20042101 |
0.556 |
|
| 2005 |
Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. Journal of Immunology (Baltimore, Md. : 1950). 174: 367-75. PMID 15611260 DOI: 10.4049/Jimmunol.174.1.367 |
0.507 |
|
| 2004 |
Su YW, Herzog S, Lotz M, Feldhahn N, Müschen M, Jumaa H. The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion. European Journal of Immunology. 34: 3614-22. PMID 15549729 DOI: 10.1002/Eji.200425445 |
0.64 |
|
| 2004 |
Kögler G, Sensken S, Airey JA, Trapp T, Müschen M, Feldhahn N, Liedtke S, Sorg RV, Fischer J, Rosenbaum C, Greschat S, Knipper A, Bender J, Degistirici O, Gao J, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. The Journal of Experimental Medicine. 200: 123-35. PMID 15263023 DOI: 10.1084/Jem.20040440 |
0.392 |
|
| 2004 |
Klein F, Feldhahn N, Müschen M. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. Cell Cycle (Georgetown, Tex.). 3: 858-60. PMID 15254401 |
0.517 |
|
| 2004 |
Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, Wernet P, Siebert R, Müschen M. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. The Journal of Experimental Medicine. 199: 673-85. PMID 14993251 DOI: 10.1084/Jem.20031637 |
0.621 |
|
| 2004 |
Klein F, Feldhahn N, Müschen M. Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. Cell Cycle. 3: 858-860. DOI: 10.4161/Cc.3.7.991 |
0.614 |
|
| 2004 |
Klein F, Feldhahn N, Wernet P, Müschen M. The BCR-ABL1 Kinase Interferes with Pre-B Cell Receptor Signal Transduction in B Cell Precursor Leukemia Cells. Blood. 104: 1894-1894. DOI: 10.1182/Blood.V104.11.1894.1894 |
0.675 |
|
| 2003 |
Schuster VH, Müschen M. Epstein-Barr virus and the B cell: a secret romance. Trends in Microbiology. 11: 243-5. PMID 12823936 DOI: 10.1016/S0966-842X(03)00121-5 |
0.582 |
|
| 2003 |
Klein F, Feldhahn N, Lee S, Wang H, Ciuffi F, von Elstermann M, Toribio ML, Sauer H, Wartenberg M, Barath VS, Krönke M, Wernet P, Rowley JD, Müschen M. T lymphoid differentiation in human bone marrow. Proceedings of the National Academy of Sciences of the United States of America. 100: 6747-52. PMID 12738882 DOI: 10.1073/Pnas.1031503100 |
0.39 |
|
| 2002 |
Feldhahn N, Schwering I, Lee S, Wartenberg M, Klein F, Wang H, Zhou G, Wang SM, Rowley JD, Hescheler J, Krönke M, Rajewsky K, Küppers R, Müschen M. Silencing of B cell receptor signals in human naive B cells. The Journal of Experimental Medicine. 196: 1291-305. PMID 12438421 DOI: 10.1084/Jem.20020881 |
0.616 |
|
| 2002 |
Müschen M, Lee S, Zhou G, Feldhahn N, Barath VS, Chen J, Moers C, Krönke M, Rowley JD, Wang SM. Molecular portraits of B cell lineage commitment. Proceedings of the National Academy of Sciences of the United States of America. 99: 10014-9. PMID 12119411 DOI: 10.1073/Pnas.152327399 |
0.574 |
|
| 2002 |
Müschen M, Rajewsky K, Krönke M, Küppers R. The origin of CD95-gene mutations in B-cell lymphoma. Trends in Immunology. 23: 75-80. PMID 11929130 DOI: 10.1016/S1471-4906(01)02115-9 |
0.515 |
|
| 2001 |
Müschen M, Küppers R, Spieker T, Bräuninger A, Rajewsky K, Hansmann ML. Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes Laboratory Investigation. 81: 289-295. PMID 11310822 DOI: 10.1038/Labinvest.3780237 |
0.495 |
|
| 2001 |
Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene. International Journal of Cancer. 92: 309-310. PMID 11291062 DOI: 10.1002/1097-0215(200102)9999:9999<::Aid-Ijc1188>3.0.Co;2-5 |
0.347 |
|
| 2001 |
Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions Blood. 97: 818-821. PMID 11157505 DOI: 10.1182/Blood.V97.3.818 |
0.539 |
|
| 2001 |
Moers C, Müschen M, Beckmann M, Mallmann P. Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene Breast Cancer Research. 3: 1-1. DOI: 10.1186/Bcr407 |
0.34 |
|
| 2001 |
Moers C, Müschen M, Beckmann M, Mallmann P. CD95 ligand expression mediates immune escape in breast cancer. Breast Cancer Research. 3: 1-1. DOI: 10.1186/Bcr406 |
0.355 |
|
| 2001 |
Moers C, Müschen M, Beckmann M, Mallmann P. CD95 ligand expression in dedifferentiated breast cancer Breast Cancer Research. 3: 1-1. DOI: 10.1186/Bcr405 |
0.337 |
|
| 2000 |
Müschen M, Re D, Jungnickel B, Diehl V, Rajewsky K, Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction Journal of Experimental Medicine. 192: 1833-1839. PMID 11120779 DOI: 10.1084/Jem.192.12.1833 |
0.485 |
|
| 2000 |
Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. Journal of Molecular Medicine. 78: 312-325. PMID 11001528 DOI: 10.1007/S001090000112 |
0.373 |
|
| 2000 |
Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology. 99: 69-77. PMID 10651943 DOI: 10.1046/J.1365-2567.2000.00921.X |
0.359 |
|
| 2000 |
Müschen M, Rajewsky K, Bräuninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma Journal of Experimental Medicine. 191: 387-394. PMID 10637283 DOI: 10.1084/Jem.191.2.387 |
0.47 |
|
| 1999 |
Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. CD95 ligand expression in dedifferentiated breast cancer. The Journal of Pathology. 189: 378-386. PMID 10547600 DOI: 10.1002/(Sici)1096-9896(199911)189:3<378::Aid-Path439>3.0.Co;2-D |
0.334 |
|
| 1999 |
Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Involvement of soluble CD95 in Churg-Strauss syndrome. American Journal of Pathology. 155: 915-925. PMID 10487849 DOI: 10.1016/S0002-9440(10)65191-7 |
0.368 |
|
| 1999 |
Muschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Haussinger D. Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation Gastroenterology. 116: 666-677. PMID 10029626 DOI: 10.1016/S0016-5085(99)70189-7 |
0.381 |
|
| 1999 |
Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D. Regulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin International Journal of Cancer. 80: 564-572. PMID 9935158 DOI: 10.1002/(Sici)1097-0215(19990209)80:4<564::Aid-Ijc14>3.0.Co;2-X |
0.433 |
|
| 1998 |
Josien R, Douillard P, Guillot C, Müschen M, Anegon I, Chetritt J, Menoret S, Vignes C, Soulillou JP, Cuturi MC. A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. Journal of Clinical Investigation. 102: 1920-1926. PMID 9835616 DOI: 10.1172/Jci4221 |
0.451 |
|
| 1998 |
Müschen M, Warskulat U, Schmidt B, Schulz WA, Häussinger D. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon gamma and all-trans retinoic acid. Biological Chemistry. 379: 1083-1091. PMID 9792441 DOI: 10.1515/Bchm.1998.379.8-9.1083 |
0.376 |
|
| 1998 |
Muschen M, Warskulat U, Douillard P, Gilbert E, Hussinger D. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells Hepatology. 27: 200-208. PMID 9425938 DOI: 10.1002/Hep.510270131 |
0.39 |
|
| Show low-probability matches. |